BMC Gastroenterology · 2023 · 12 citations · 22 references
MedicinePharmacologyPharmacotherapyImmunopathologyImmunoregulationInflammationAnti-inflammatory PharmacologyGastrointestinal InflammationGastrointestinal PharmacologyInflammation PharmacologyInflammatory Bowel DiseaseMucosal InflammationGlucagon-like PeptidesInflammatory Bowel Disease ModelsInflammatory Bowel Disease PathophysiologyInflammatory Bowel Disease TherapyInflammatory Bowel SyndromeLong-acting Glp-1 Receptor AgonistsSmall Intestinal FunctionSmall Intestinal Physiology
BACKGROUND: Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for treatment of short bowel syndrome. Here, we investigated if glepaglutide is therapeutically beneficial in rats with small intestinal inflammation. METHODS: Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages. Glepaglutide was administered in co-treatment and post-treatment regimens. Small intestinal length and concentrations of inflammatory markers α-1-acid glycoprotein and myeloperoxidase were used to assess anti-inflammatory effects. Small intestinal mass was evaluated to determine intestinotrophic effects. RESULTS: Glepaglutide co- and post-treatment significantly reduced severity of small intestinal inflammation, evidenced by reversed small intestinal shortening and decreased α-1-acid glycoprotein and/or myeloperoxidase concentration(s). Co- and post-treatment with glepaglutide also significantly increased small intestinal mass, indicating intestinal regenerative effects. Similar effects were observed in naive rats after glepaglutide treatment. CONCLUSION: Glepaglutide has anti-inflammatory and intestinotrophic effects without the need for pre-treatment in a rat model of small intestinal inflammation. Thus, glepaglutide is of potential clinical interest for patients with IBD.
22
Sudabeh Alatab, Sadaf G Sepanlou, Kevin S Ikuta et al. · The Lancet. Gastroenterology & hepatology · 2019 · 2.3K citations · Full text
Public Health, Chronic Disease Prevention, Health Sciences +17
Cancer risk in patients with inflammatory bowel disease
Çharles N. Bernstein, James Blanchard, Erich V. Kliewer et al. · Cancer · 2001 · 1.2K citations · Full text
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents
Bernardo Yusta, Lilly Huang, Donald G. Munroe et al. · Gastroenterology · 2000 · 339 citations · Full text